Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial Redazione 16 Giugno 2022 ...
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial Redazione 16 Giugno 2022 ...
A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease Redazione 16 Giugno 2022 ...
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort Federica Passarelli 9 Giugno 2022 ...
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics Redazione 19 Maggio 2022 ...
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study Redazione 19 Maggio 2022 ...
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia Redazione 5 Maggio 2022 ...
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry Redazione 5 Maggio 2022 ...
